Cardiology: clinical trials and reviews
Acute and chronic effects of molsidomine retard and molsidomine non retard on exercise capacity and clinical status in patients with stable angina: a multicentric randomized double-blind cross-over placebo-controlled trial,
Journal of Cardiovascular Pharmacology, 31, 2, 271-276, (1998).
Treatment of mild to moderate hypertension by pinacidil: a multicentre open clinical trial in daily practice,
Journal of Clinical Research, 1, 55-61, (1998).
Treatment of mild-to-moderate arterial hypertension with pinacidil alone or in combination with hydrochlorothiazide,
Current Therapeutic Research, 59(5), 269-274, (1998).
Efficacy and safety of molsidomine 16 mg once-a-day as monotherapy in patients with stable angina: a randomized double-blind trial against molsidomine 8 mg twice-a-day and placebo,
International Journal of Cardiology, 98(1), 79-89,(2005).
Age-dependent therapeutic effects of once-daily molsidomine used as an add-on treatment in patients with stable angina pectoris, Heart Drug, 4(4), 184-189 (2004).
A pilot double-blind randomized placebo-controlled study of molsidomine 16 mg once-a-day in patients suffering from stable angina pectoris: correlation between efficacy and over time plasma concentrations, European Journal of Clinical Pharmacology, 59, 227-232, (2003).
Efficacy and safety of the freeze-dried cultured human keratinocyte lysate, LyphoDerm 0.9%, in the treatment of hard-to-heal venous leg ulcers, Wound Repair and Regeneration, 13(2), 138-147, (2005).
Long-term treatment with the NO-donor molsidomine reduces circulating ICAM-1 levels in patients with stable angina, Atherosclerosis, 180(2), 399-405 (2005).
Therapeutic potential of nitric oxide donors in the prevention and treatment of atherosclerosis, European Heart Journal, 26(19), 1945-1955 (2005).
Efficacy and safety of once- and twice-daily formulations of molsidomine in patients with stable angina pectoris: double-blind and open-label studies, Advances in Therapy, 23(1), 107-130 (2006).
Tolerability to 1-year treatment with once-daily molsidomine in patients with stable angina, Advances in Therapy, 23(4), 601-614 (2006).
Comparative effects of once-daily molsidomine in coronary patients from two distinct European Ethnicities, Advances in Therapy, 25(11), 1200-1214 (2008).
Double-blind parallel placebo-controlled study to evaluate the effect of molsidomine on the endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: The MEDCOR trial, Journal of Cardiovascular Translational Research, 7(2), 226-231 (2014).
Long-term effect of molsidomine, a direct nitric oxide donor, as an add-on treatment, on endothelial dysfunction in patients with stable angina pectoris undergoing percutaneous coronary intervention: results of the MEDCOR trial, Atherosclerosis, 240(2): 351-354 (2015).